Weavewell

For reference only · Not medical advice

Sources include the CDC, FDA, HIV.gov, Australian STI Management Guidelines, PubMed-indexed research, and other linked references.

Infection

Hepatitis A

Hepatitis A virus

Source evidence review: 2026-10-26. Source links are provided for transparency; guidance can change.

Stylized hepatitis A virus over a liver silhouette: small, bare, geometric particles with no envelope. Not to scale; not diagnostic.

FECAL-ORAL, VACCINE-PREVENTABLE INFECTION / CARE & TRANSMISSION

Hepatitis A virus (HAV)

Hepatitis A spreads when microscopic fecal material reaches the mouth, including during some sexual practices. It causes an acute liver infection but does not become chronic. Vaccination and prompt postexposure care are more useful than trying to estimate a sexual per-act percentage. [49][50]

Transmission risk

Risk by type of contact

Bottom line. HAV is a fecal-oral infection that can spread during sex, particularly through rimming and contaminated hands or toys. Vaccination has strong evidence; a condom alone does not control all relevant exposure pathways.

Type of contact

General

No barrier

Sexual transmission is predominantly fecal-oral: infectious material must reach the mouth.*

  • No numeric estimate
  • Evidence: Low

Susceptible recipient; source shedding HAV in stool, including before recognized illness.

Sources 1

With a barrier

Barriers can interrupt some fecal-oral contact, but no condom/dam effectiveness percentage is established.*

  • No numeric estimate
  • Evidence: Low

Hands, toys, adjacent skin and sequential acts can bypass a barrier.

Sources 1, 2

Oral

No barrier

Rimming is a recognized fecal-oral exposure; contaminated oral-genital contact can also expose the mouth.*

  • No numeric estimate
  • Evidence: Low

Not all oral sex has equal fecal exposure. No per-rimming-act denominator.

The person whose mouth contacts contaminated anus/skin is directly exposed; no quantified reverse-direction estimate.

Sources 1, 2

With a barrier

A dam may block the covered anus-mouth pathway, but no HAV-specific clinical efficacy estimate exists.*

  • No numeric estimate
  • Evidence: Low

Fresh intact barrier with careful handling; contaminated hands/skin remain relevant.

Sources 2

Vaginal

No barrier

Isolated vaginal penetration is not the characteristic transmission route; risk is through associated fecal-to-mouth transfer.*

  • No numeric estimate
  • Risk: Negligible
  • Evidence: Low

No oral contamination or other acts assumed for the isolated-route statement.

Sources 1

With a barrier

A penile condom does not control all fecal-oral pathways elsewhere in the encounter.*

  • No numeric estimate
  • Evidence: Low

No HAV-specific vaginal condom effect size.

Sources 1, 2

Anal

No barrier

Anal activity can contaminate skin, hands or toys that subsequently reach the mouth; penetration alone is not the same as fecal ingestion.*

  • No numeric estimate
  • Evidence: Low

Actual fecal-oral transfer determines exposure; do not equate all anal acts.

No validated receptive/insertive acquisition probabilities.

Sources 1, 2

With a barrier

Condoms can reduce contamination of the covered penis/toy but do not prevent every hand-to-mouth or oral-anal exposure.*

  • No numeric estimate
  • Evidence: Low

No HAV-specific anal condom effect size.

Sources 2, 1

Kissing

No barrier

Ordinary kissing is not the typical HAV route; a contaminated mouth after fecal exposure is a different situation.*

  • No numeric estimate
  • Risk: Negligible
  • Evidence: Low

No fecal contamination assumed for ordinary kissing.

Sources 1

With a barrier

Not applicable: condoms and dental dams used for other acts do not protect a separate kissing exposure. No studied kissing-barrier effectiveness estimate.*

  • No numeric estimate
  • Evidence: Low

A separate oral barrier is not a validated kissing intervention; do not render this as a reduced-risk numerical cell.

Sources 1

What changes the risk (3)
  • Vaccination. HIGH across vaccine trials: CDC summarizes 94% efficacy in a Thai trial and 100% in a New York trial against clinical hepatitis A. Different trials, not a pooled percentage; not per-sex-act prevention estimates. Sources 1
  • Postexposure prophylaxis. LOW for a sexual-exposure percentage: vaccination and sometimes immune globulin within two weeks can prevent disease; indication depends on age, immunity and clinical context. Sources 3
  • Rimming and hygiene. LOW for numerical effect: fecal contamination of mouth, hands, toys or skin is the actionable pathway. No general handwashing, dam or rimming risk-reduction percentage. Sources 2, 1
Condoms and dental dams

No HAV-specific condom/dental-dam clinical effectiveness estimate. Barriers address covered contact, whereas vaccination and avoiding fecal-to-mouth transfer address the infection more broadly. Evidence: Low Sources 2, 1

Sources for this risk profile (3)
  1. Foster MA, Haber P, Nelson NP; CDC Pink Book, 2024. Chapter 9: Hepatitis A. cdc.gov
  2. CDC CDC, 2024. About STI Risk and Oral Sex. cdc.gov
  3. CDC CDC, 2025. Clinical Care of Hepatitis A. cdc.gov

* How to read these figures. Each is a published estimate under the conditions shown beside it, usually an untreated partner and a single act or partnership. It is not a prediction of your personal risk.

Evidence: High
Several prospective studies or a systematic review broadly agree.
Evidence: Medium
One or two studies, wide uncertainty, or a model.
Evidence: Low
Guideline judgment, case reports, or extrapolation.

Where no risk level is shown, the evidence cannot rank it. That is not the same as low.

Evidence reviewed through 2026-10-27. For reference only; not medical advice.

When to test after a possible exposure

Diagnostic testing is symptom- and exposure-directed; there is no routine post-sex all-clear testing day.

When to be seen sooner. After contact with hepatitis A, vaccine or immune globulin helps most within 2 weeks, so it is worth asking early rather than waiting for symptoms or a test.

  • IgM anti-HAV; RNA in selected diagnostic/public-health settings

    • Timed from symptoms
    • Evidence: Medium

    IgM anti-HAV is typically present about 5-10 days before symptoms, not at a fixed number of days after the contact.

    Use testing for suspected acute illness as clinically indicated; do not convert this symptom-relative timing into a universal exposure-based window.

    Specimens: Blood; stool for selected RNA testing

    Sources 1

Early negatives, after treatment, and screening limits

An early negative result. An early negative does not exclude incubating illness. Further testing depends on the clinical course.

After treatment. IgM can remain detectable after acute infection; antibody positivity is not an immediate measure of ongoing infectiousness or a routine test-of-cure.

Screening limits. Routine IgM screening in asymptomatic people is not recommended; immunity testing is a separate question.

Kissing and body sites. Relevant sexual exposure is fecal-oral, including rimming or contamination; there is no validated kissing-specific screening interval.

Sources for testing guidance (2)
  1. CDC. Clinical Screening and Diagnosis for Hepatitis A. 2024. cdc.gov
  2. CDC. Clinical Care of Hepatitis A. 2025. cdc.gov

Treatment

There is no specific antiviral cure for uncomplicated hepatitis A; care is usually supportive. Hydration and clinical monitoring matter, and a clinician should review medicines and alcohol use during liver illness. Severe disease, dehydration or existing liver disease can require hospital care. [49]

Actions

1. Check vaccine protection. Vaccination is especially useful when practices or local outbreaks increase fecal-oral exposure. After a known exposure, vaccine and sometimes immune globulin help when given within two weeks, so it is worth asking promptly. [49][50]

2. Tell the right contacts. Public health or the treating clinic can advise which household and sexual contacts to tell. People are usually infectious from about two weeks before illness until about a week after jaundice or illness starts; the exact window depends on the case. [49]

3. Reduce fecal-oral contact. Wash hands with soap and water and clean shared equipment. During the infectious period, avoid sex that could expose others, and follow public-health advice about clearance and about preparing food for others. [49][50]

SCIENCE & CONTEXT

Hepatitis A / the evidence

History

Clinicians distinguished infectious hepatitis from other hepatitis syndromes before the virus itself was identified in the 1970s. The first US hepatitis A vaccine was licensed in 1995. Modern outbreak control combines vaccination, contact management and hygiene; the infection is not confined to any sexual identity or relationship structure. [49][50]

Impact

HAV infects the liver after fecal-oral acquisition. Adults may experience fever, fatigue, nausea, abdominal discomfort, dark urine and jaundice. Illness can be prolonged, but chronic infection does not occur. Older age and underlying liver disease increase the risk of severe outcomes. [49]

People can be infectious before they know they are ill. This makes a symptom-only strategy insufficient during an outbreak. Antibody testing also distinguishes acute infection from immunity: IgM anti-HAV supports recent infection, while prior vaccination or infection may produce lasting protective antibodies. [49]

Probability at a glance

Situation Useful prevention / interpretation

Susceptible, before exposure

Vaccination provides durable prevention

Known exposure within 14 days

Prompt vaccine and/or immune globulin assessment

Past vaccine or resolved infection

Immunity differs from acute infectiousness

Suspected acute illness

Clinical assessment and IgM testing when appropriate

No defensible six-month sexual-network prevalence is assigned. Susceptibility and a specific outbreak or known contact are more relevant than generic partner count. [49][50]

In short: check immunity before an exposure when you can, and after one, ask about prevention within two weeks.